[Advances in lung cancer].

Sessions about lung cancer of the 28th annual meeting of ASCO approached especially non small cell lung cancer (NSCLC). Undoubtedly the outstanding facts for this pathology was first the acknowledgment of the importance of a correct staging system, in particular in stage IIIA for which resection is a prognostic factor different for tumors T3N0, T3N1 as for N2. Two important topics have been discussed on therapy: stage IIIA treatment, in particular neoadjuvant therapy before surgery, and new drugs like Navelbine, taxol, and campthotecine which suggest the possibility of improvements for chemotherapy of NSCLC in the next few years. For small cell lung cancer (SCLC), different trials were designed to improve dose intensity with growth factors, fractionation of therapy, autologous bone marrow transplantation.